Health Secretary Wes Streeting has dismissed suggestions that plans to provide weight loss jabs to unemployed people with obesity are “dystopian.”.

The UK government is launching a five-year trial with pharmaceutical giant Lilly to test if the weight-loss drug Mounjaro can help get more people back to work and ease the strain on the NHS in England by preventing obesity-related diseases.

The announcement prompted a backlash, with accusations that the government was stigmatising unemployed individuals and reducing people to their economic value.

Speaking on Sunday with Laura Kuenssberg, Streeting said the jabs were part of a broader healthcare plan, adding that he was “not interested in some dystopian future where I involuntarily jab unemployed people who are overweight”.

“There’s a lot of evidence already that these jabs combined with changes to diet and exercise can help people to reduce their weight but also prevent cardiovascular disease and also diabetes which is game-changing,” Streeting said.

But he cautioned against creating a “dependency culture”.

Some injections are already prescribed on the NHS for the treatment of obesity, and also for people with diabetes.

Prime Minister Sir Keir Starmer previously told the BBC the jabs would be “very helpful” to people who want and need to lose weight.

“[The drug is] very important for our NHS, because, yes we need more money for the NHS, but we’ve also got to think differently”.

The NHS’s latest Health Survey for England shows in 2022, 29% of adults in England were obese and 64% were deemed to be overweight.

Illnesses relating to obesity cost the NHS £11bn a year, Streeting said.

Obesity has also been linked to the development of type 2 diabetes, with the NHS spending around £10bn a year – 9% of its budget – to care for people with diabetes.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

what is 3 in addition to 3?

Explore More

Implantable microparticles can deliver two cancer therapies at once

Patients with late-stage cancer often have to endure multiple rounds of different types of treatment, which can cause unwanted side effects and may not always help. In hopes of expanding

Focus on puberty blockers in gender care disproportionate, Cass says

Getty Images The focus on puberty blockers in the gender-care debate is disproportionate, the paediatrician who led the NHS review into children’s services, says. Dr Hilary Cass said the merits

Just a moment…

Just a moment… Enable JavaScript and cookies to continue This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until